Alexiou George A, Gerogianni Paraskevi, Vartholomatos Evrysthenis, Kyritsis Athanasios P
a Neurosurgical Institute, University of Ioannina , Ioannina , Greece.
Cancer Invest. 2016 Nov 25;34(10):489-495. doi: 10.1080/07357907.2016.1233424. Epub 2016 Oct 21.
Glioblastoma is the most malignant primary brain tumor with a median survival of 15 months. Temozolomide (TMZ) is the standard of care for these patients. Iron chelators have been shown to have anti-tumor activity; however, deferiprone (DFP), an orally administered iron chelator, has not been previously evaluated in gliomas. In the present study, we found that combination treatment in glioma cells with TMZ and DFP significantly reduced cell viability, produced cell cycle arrest at G2/M phase, and enhanced apoptosis. TMZ and DFP might be a potent new combination treatment for glioblastoma.
胶质母细胞瘤是最恶性的原发性脑肿瘤，中位生存期为15个月。替莫唑胺（TMZ）是这些患者的标准治疗药物。铁螯合剂已显示出具有抗肿瘤活性；然而，去铁酮（DFP），一种口服铁螯合剂，此前尚未在胶质瘤中进行评估。在本研究中，我们发现胶质瘤细胞中TMZ与DFP联合治疗显著降低细胞活力，使细胞周期停滞在G2/M期，并增强细胞凋亡。TMZ和DFP可能是胶质母细胞瘤一种有效的新联合治疗方法。
